139 related articles for article (PubMed ID: 19656163)
1. BRCA2 alteration is important in clear cell carcinoma of the ovary.
Goodheart MJ; Rose SL; Hattermann-Zogg M; Smith BJ; De Young BR; Buller RE
Clin Genet; 2009 Aug; 76(2):161-7. PubMed ID: 19656163
[TBL] [Abstract][Full Text] [Related]
2. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
3. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer.
Kang S; Dong SM; Park NH
Gynecol Oncol; 2010 Jul; 118(1):58-63. PubMed ID: 20421128
[TBL] [Abstract][Full Text] [Related]
4. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
Evans DG; Young K; Bulman M; Shenton A; Wallace A; Lalloo F
Clin Genet; 2008 Apr; 73(4):338-45. PubMed ID: 18312450
[TBL] [Abstract][Full Text] [Related]
5. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.
Esteban Cardeñosa E; Bolufer Gilabert P; Palanca Suela S; Oltra Soler S; Barragán González E; Velasco Sampedro E; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E;
Breast Cancer Res Treat; 2008 Nov; 112(1):69-73. PubMed ID: 18060494
[TBL] [Abstract][Full Text] [Related]
6. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
Pejovic T; Yates JE; Liu HY; Hays LE; Akkari Y; Torimaru Y; Keeble W; Rathbun RK; Rodgers WH; Bale AE; Ameziane N; Zwaan CM; Errami A; Thuillier P; Cappuccini F; Olson SB; Cain JM; Bagby GC
Cancer Res; 2006 Sep; 66(18):9017-25. PubMed ID: 16982743
[TBL] [Abstract][Full Text] [Related]
8. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
9. Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma.
Akbari MR; Malekzadeh R; Nasrollahzadeh D; Amanian D; Islami F; Li S; Zandvakili I; Shakeri R; Sotoudeh M; Aghcheli K; Salahi R; Pourshams A; Semnani S; Boffetta P; Dawsey SM; Ghadirian P; Narod SA
Oncogene; 2008 Feb; 27(9):1290-6. PubMed ID: 17724471
[TBL] [Abstract][Full Text] [Related]
10. The role of p53 mutation in the carcinomas arising from endometriosis.
Akahane T; Sekizawa A; Purwosunu Y; Nagatsuka M; Okai T
Int J Gynecol Pathol; 2007 Jul; 26(3):345-51. PubMed ID: 17581423
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression.
Kato N; Motoyama T
Histopathology; 2008 May; 52(6):682-8. PubMed ID: 18393978
[TBL] [Abstract][Full Text] [Related]
12. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.
Veras E; Mao TL; Ayhan A; Ueda S; Lai H; Hayran M; Shih IeM; Kurman RJ
Am J Surg Pathol; 2009 Jun; 33(6):844-53. PubMed ID: 19342944
[TBL] [Abstract][Full Text] [Related]
13. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
14. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.
Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J
J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of BRCA2 gene mutations among familial and/or early-onset breast cancer patients in eastern Shandong of China].
Ma ZL; Cao MZ; Li WF
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):195-8. PubMed ID: 18393245
[TBL] [Abstract][Full Text] [Related]
16. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization.
Kresse SH; Ohnstad HO; Paulsen EB; Bjerkehagen B; Szuhai K; Serra M; Schaefer KL; Myklebost O; Meza-Zepeda LA
Genes Chromosomes Cancer; 2009 Aug; 48(8):679-93. PubMed ID: 19441093
[TBL] [Abstract][Full Text] [Related]
17. Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Uehara Y; Oda K; Ikeda Y; Koso T; Tsuji S; Yamamoto S; Asada K; Sone K; Kurikawa R; Makii C; Hagiwara O; Tanikawa M; Maeda D; Hasegawa K; Nakagawa S; Wada-Hiraike O; Kawana K; Fukayama M; Fujiwara K; Yano T; Osuga Y; Fujii T; Aburatani H
PLoS One; 2015; 10(6):e0128066. PubMed ID: 26043110
[TBL] [Abstract][Full Text] [Related]
18. Novel variations and loss of heterozygosity of BRCA2 identified in a dog with mammary tumors.
Yoshikawa Y; Morimatsu M; Ochiai K; Nagano M; Tomioka Y; Sasaki N; Hashizume K; Iwanaga T
Am J Vet Res; 2008 Oct; 69(10):1323-8. PubMed ID: 18828690
[TBL] [Abstract][Full Text] [Related]
19. cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
Zhang L; Bacares R; Boyar S; Hudis C; Nafa K; Offit K
Mutat Res; 2009 Apr; 663(1-2):84-9. PubMed ID: 19070627
[TBL] [Abstract][Full Text] [Related]
20. Association of decreased mitochondrial DNA content with ovarian cancer progression.
Wang Y; Liu VW; Xue WC; Cheung AN; Ngan HY
Br J Cancer; 2006 Oct; 95(8):1087-91. PubMed ID: 17047655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
